IGF-LR3 (Insulin-like Growth Factor-I Long-R3, also designated Long-R3-IGF-I) is a recombinant analog of human IGF-I comprising 83 amino acids — 13 additional residues at the N-terminus relative to mature IGF-I (70 AA), with a substitution of glutamic acid for arginine at position 3 of the native sequence. The molecule was engineered by researchers at GroPep Ltd. (Adelaide, Australia) and described by Francis et al. (1992) with the specific research objective of creating an IGF-I analog with dramatically reduced affinity for insulin-like growth factor binding proteins (IGFBPs) while maintaining high-affinity binding to the IGF-1 receptor (IGF1R).
The resulting analog exhibits approximately 2–3 times greater potency than native IGF-I in cell proliferation assays, attributable to its resistance to sequestration by the six high-affinity IGFBPs that normally buffer and regulate free IGF-I availability in biological fluids. This property has made IGF-LR3 the preferred IGF-I analog for cell culture research applications where consistent, IGFBP-independent receptor stimulation is required — including serum-free cell culture medium formulations, bioreactor optimization for cell line expansion, and mechanistic studies of IGF1R downstream signaling pathways.
Biochemical Identity & Structural Properties
| Property | Value |
|---|---|
| Full Name | Long-R3 Insulin-like Growth Factor-I / IGF-LR3 / Long-R3-IGF-I |
| Length | 83 amino acids |
| Molecular Weight | ~9,111 Da |
| CAS Number | 206181-80-8 |
| Modifications vs. IGF-I | 13-AA N-terminal extension; Arg3→Glu3 substitution |
| Disulfide bonds | 3 intramolecular disulfide bonds (identical to IGF-I: Cys6–Cys48, Cys18–Cys61, Cys47–Cys52) |
| IGFBP affinity | >1000-fold reduced vs. native IGF-I |
| IGF1R affinity | Comparable to native IGF-I; slightly enhanced in some assays |
| Solubility | Dissolves in 10 mM acetic acid or dilute HCl; then dilute in neutral buffer |
| Storage (lyophilized) | −20°C, desiccated, protected from light |
Proposed Mechanisms of Action
IGF-1 Receptor (IGF1R) Activation and Downstream Signaling
IGF-LR3 binds the IGF-1 receptor (IGF1R) — a receptor tyrosine kinase — with affinity comparable to native IGF-I. Ligand binding induces receptor dimerization, autophosphorylation of intracellular kinase domain tyrosines (Tyr1158, Tyr1162, Tyr1163), and recruitment of insulin receptor substrate (IRS-1/IRS-2) scaffold proteins. Published cell culture research has characterized the downstream signaling cascades activated by IGF-LR3 IGF1R stimulation: PI3K/AKT/mTORC1 phosphorylation (associated with protein synthesis and cell survival), MAPK/ERK1/2 activation (associated with cell cycle progression and proliferation), and S6 kinase-mediated translational upregulation. Because IGF-LR3 bypasses IGFBP sequestration, these signaling studies can be conducted with well-defined free-ligand concentrations — a significant technical advantage in mechanistic research.
IGFBP Resistance and Cell Culture Applications
The critical structural determinant of IGF-LR3's utility as a research tool is the N-terminal extension combined with the Arg3→Glu3 substitution, which together disrupt the primary IGFBP binding surfaces of the IGF-I molecule. Research by Francis et al. established that native IGF-I's N-terminal domain contributes a major IGFBP binding interface (the Gln3 residue being particularly important for IGFBP-3 and IGFBP-5 interactions). The Long-R3 modifications reduce IGFBP-3 binding affinity by >1000-fold and similarly impair binding to IGFBP-1, -2, -4, -5, and -6. In cell culture systems that contain serum (which carries abundant IGFBPs), IGF-LR3 delivers substantially greater biological activity per mass unit than native IGF-I because it remains in free, receptor-available form rather than being buffered in IGFBP complexes.
GH-Independent Anabolic Signaling Research
The GH/IGF-1 axis research field has employed IGF-LR3 to dissect GH-dependent versus GH-independent contributions to anabolic signaling in skeletal muscle, bone, and liver cell models. By providing a defined, IGFBP-independent IGF1R stimulus, researchers can characterize the cell-autonomous component of IGF-1 receptor signaling — its effects on protein synthesis rate (measured via puromycin incorporation or SUnSET assay), myofibrillar protein gene expression (MyoD, myogenin, MHC isoforms in myocyte cultures), and cell cycle regulation — independently of GH receptor activation and its multiple non-IGF-1-mediated effects. This research design approach has contributed to understanding how local IGF-1 signaling drives muscle cell hypertrophy programs in vitro.
Summary of Published Research Findings
- Cell proliferation potency characterization: Francis et al. (1992) originally demonstrated that IGF-LR3 was approximately 2–3 times more potent than native IGF-I in stimulating [³H]-thymidine incorporation (DNA synthesis) in rat L6 myoblasts — attributable to reduced IGFBP sequestration in serum-containing media, establishing the pharmacological foundation for its research utility.
- Serum-free medium supplementation: Biopharmaceutical cell culture research has employed IGF-LR3 as a defined-medium supplement to support CHO, HEK293, and hybridoma cell line growth in the absence of serum, enabling controlled studies of IGF1R-dependent cell survival and proliferation signaling pathways.
- PI3K/mTOR pathway research: Cell culture studies using IGF-LR3 stimulation with pathway-selective inhibitors (LY294002, rapamycin, torin1) have mapped the hierarchy of signaling events downstream of IGF1R activation, characterizing AKT phosphorylation kinetics, mTORC1/mTORC2 substrate selectivity, and S6K1-4EBP1 axis activity in multiple cell types.
- Myogenesis and satellite cell research: Primary muscle satellite cell and C2C12 myoblast studies have used IGF-LR3 to examine IGF1R contribution to myoblast differentiation, myotube formation, and myofibrillar protein accretion in vitro.
Key Published References
Francis GL, Ross M, Ballard FJ, et al. (1992). Novel recombinant fusion protein analogues of insulin-like growth factor (IGF)-I indicate the relative importance of IGF-binding protein and receptor binding for enhanced biological potency. Journal of Molecular Endocrinology, 8(3), 213–223. PMID: 1380384
Tomas FM, Knowles SE, Owens PC, et al. (1993). Increased weight gain, nitrogen retention and muscle protein synthesis following treatment of diabetic rats with insulin-like growth factor (IGF)-I and des(1-3)IGF-I. Biochemical Journal, 291(Pt 3), 781–786. PMID: 8489494
Firth SM, Baxter RC. (2002). Cellular actions of the insulin-like growth factor binding proteins. Endocrine Reviews, 23(6), 824–854. PMID: 12466191
Storage & Laboratory Handling
- Lyophilized powder: −20°C in desiccated, light-protected conditions. The three disulfide bonds are stable under lyophilized storage conditions.
- Reconstitution: Dissolve at 0.1 mg/mL in 10 mM acetic acid (pH ~3.5) initially, then dilute to working concentration in PBS or culture medium. Avoid dissolving directly in neutral or basic buffers — the hydrophobic IGF-I core requires mild acid for initial solubilization.
- Working solutions: Carrier protein (0.1% BSA) recommended to prevent adsorption to plastic surfaces at low concentrations (<10 ng/mL). Store working aliquots at −80°C; avoid repeated freeze-thaw. Reducing agents (DTT, β-ME) will destroy the disulfide bonds — avoid in working buffers.
